MRI for solitary pulmonary nodule and mass assessment: Current state of the art

<jats:sec><jats:label /><jats:p>Since the clinical introduction of magnetic resonance imaging (MRI), the chest has been one of its most challenging applications, and many physicists and radiologists have tried since the 1980s to use MR for assessment of different lung diseases as well as mediastinal and pleural diseases. Since then, however, technical advances in sequencing, scanners, and coils, adaptation of parallel imaging techniques, utilization of contrast media, and development of postprocessing tools have been reported by many basic and clinical researchers. As a result, state‐of‐the‐art thoracic MRI is now substituted for traditional imaging techniques and/or plays a complementary role in the management of patients with various chest diseases, and especially in the detection of pulmonary nodules and in thoracic oncology. In addition, MRI has continued to be developed to help overcome the limitations of computed tomography (CT) and nuclear medicine examinations. It can currently provide not only morphological, but also functional, physiological, pathophysiological, and molecular information at 1.5T with a gradual shift from 1.5T to 3T MR systems. In this review, we focus on these recent advances in MRI for pulmonary nodule detection and pulmonary nodule and mass evaluation by using noncontrast‐enhanced and contrast‐enhanced techniques as well as new molecular imaging methods such as chemical exchange saturation transfer imaging for a comparison with other modalities such as single or multidetector row CT, 18F‐fluoro‐2‐deoxyglucose positron emission tomography (FDG‐PET), and/or PET/CT.</jats:p><jats:p><jats:bold>Level of Evidence:</jats:bold> 4</jats:p><jats:p><jats:bold>Technical Efficacy:</jats:bold> Stage 2</jats:p><jats:p>J. Magn. Reson. Imaging 2018;47:1437–1458.</jats:p></jats:sec>